Extractions: AllRefer Channels :: Yellow Pages Reference Health Home ... Contact Us Quick Jump ADD/ADHD Allergies Alzheimer's Disease Arthritis Asthma Back Pain Breast Cancer Cancer Colon Cancer Depression Diabetes Gallbladder Disease Heart Attack Hepatitis High Cholesterol HIV/AIDS Hypertension Lung Cancer Menopause Migraines/Headaches Osteoporosis Pneumonia Prostate Cancer SARS Stroke Urinary Tract Infection 1600+ More Conditions Alternative Medicine Health News Symptoms Guide Special Topics ... Medical Encyclopedia Go To Main Page Alternate Names : Idiopathic Nephrotic Syndrome of Childhood, Lipoid Nephrosis, Minimal Change Nephrotic Syndrome, Nil Disease Definition Minimal change disease is a kidney disorder. Each kidney is made of more than a million units called nephrons. Each nephron has a tuft of blood vessels called a glomerulus, which is surrounded by a Bowman's Capsule. Together, these structures filter blood and form urine. Minimal change disease is one cause of nephrotic syndrome . It is named "minimal change" because the nephrons appear totally normal under a light microscope. The condition is only seen using an electron microscope, which reveals changes in the Bowman's Capsule in the nephrons. Urine tests also show high protein levels.
Nefrología. Volumen 4/99 Casos Clínicos. Art.2 Translate this page Kidney Int 33 708-715, 1998. ·4.·Kashgarian M lipoid nephrosis and focal sclerosisdistinct entities or spectrum of disease. Nephron 13 105-108, 1974. http://www.aulamedica.es/nefrologia/nefro2-00/comunic1e.htm
Extractions: Cuba Subir Las nefropatías glomerulares primarias ocupan un lugar preponderante en el campo de la Nefrología, ya que constituyen una de las primeras causas de insuficiencia renal crónica . Aunque la etiología de este conjunto de enfermedades no está totalmente dilucidada en el momento actual, su patogenia, aun siendo compleja, está mejor conocida, ya que a partir de los trabajos de Brenner han emergido un conjunto de conocimientos sobre los mecanismos de lesión glomerular, desencadenados a partir de estímulos, sean éstos de carácter inmunológico o de otra índole, que conllevan en última instancia la pérdida de unidades funcionales
Arch Intern Med -- Abstracts: Hulter And Bonner 140 (3): 403 lipoid nephrosis appearing as acute oliguric renal failure. HN Hulterand EL Bonner Jr. Acute oliguric renal failure previously was http://archinte.ama-assn.org/cgi/content/abstract/140/3/403
Extractions: Vol. 140 No. 3, March 1, 1980 Featured Link E-mail Alerts ARTICLE Article Options Send to a Friend Similar articles in this journal Literature Track Add to File Drawer Download to Citation Manager PubMed citation Articles in PubMed by Hulter HN Bonner EL Articles that cite this article Contact me when this article is cited H. N. Hulter and E. L. Bonner Jr Acute oliguric renal failure previously was reported to develop in patients with preexisting idiopathic nephrotic syndrome in association with clinical evidence of vascular volume depletion. We describe an 81-year-old man without recent proteinuria or evidence of preexisting nephrotic syndrome in whom acute oliguric renal failure developed. Renal biopsy disclosed minimal change disease. Nephrotic range proteinuria without severe hypoalbuminemia
Extractions: Next Back Home Patient Recruitment Stopped Conventional therapy protocols are assigned to a patient by random numbers in the case of several available treatment modalities for one and the same form of glomerulonephritis. The treatment effect is compared by a randomized, controlled, open trial. The randomization is done on-site at each centre by a computer program (random number generator). The inclusion criteria for the treatment following the underneath mentioned therapy protocol are: For all glomerular diseases except IgA-Nephropathy: 1. Proteinuria over 3.5 g/die, measured three times in series IgA-Nephropathy: Histologically proven diagnosis independently of serum creatinine or proteinuria. If inclusion criteria are not given and the patient is suffering from biopsy proven glomerulonephritis patients data and follow-up are nevertheless registered in the central data bank. Analysis on this subgroup of patients will be performed separately. The study endpoint is determined five years after inclusion. An intermittent analysis of the data will be done after six months.
Extractions: Lab 3 Slides 70 Slides 51 Supplement ... Slides 28 Welcome to the Systemic Pathology Laboratory #3: Renal, Urinary Disease, and Male GU Please select a slide group to view by clicking on the appropriate slide button or text found on the left or top navigation bars. The contents of the each slide group are listed in the index below. Alternatively, you can click on the continue text below to proceed to the first slide group. To return to the Pathology Course Menu select from the text navigator bar below. Slides 70: Glomerulonephritis, Rapidly Progressive Slides 51: Membranous Glomerulopathy Supplement : No Glass Slides Slide 41: Acute Proliferative Glomerulonephritis, with Early Crescents Slides 40: Polycystic Disease (Adult, Autosomal Dominant) Slides 28: Prostate: Adenocarcinoma Continue to Slide 70 Lab 3 Slides 70 Slides 51 ... UMDNJ
Nephrology Terms entry LifeSite hemodialysis venous access system see MT Desk glossary entryline of Toldt lipoid nephrosis minimal-change disease lithium Lithospec http://www.mtdesk.com/lstneph.shtml
X. DISEASES OF THE GENITOURINARY SYSTEM NEPHRITIS, NEPHROTIC glomerulonephritis mixed membranous and proliferative glomerulonephritis 581.3 Withlesion of minimal change glomerulonephritis lipoid nephrosis Minimal change http://www.nber.org/mortality/1995/docs/ch10.txt
Surgery Of Modern Warfare There is a disease of the kidneys that used to be called lipoid nephrosis, andit causes children to present with swelling all over their bodies and renal http://www.surgeryofmodernwarfare.com/archives/july2103/july2103.html
NEPHRITIC And NEPHROTIC SYNDROMES Age Group Affected, Treatment and Outcome. NEPHROTIC SYNDROME Proteinuria, Hypoalbuminemia,Edema, Hyperlipidemia. Minimal Change Disease (lipoid nephrosis). http://www.student.med.umn.edu/class2001/nephrotic-nephritic.htm
Extractions: Edema, Hyperlipidemia Minimal Change Disease (Lipoid Nephrosis) Loss of foot processes Loss of GBM polyanionic sites Appearance of villi on epithelial cells Normal Lipid in tubules F.M. = negative E.M. = loss of foot processes, lipid vacuoles #1 cause of Nephrotic Syndrome in children, esp. boys younger than 6 yrs. old. Responds well to corticosteroids. No progression into chronic renal failure Focal Segmental Glomerular Sclerosis Idiopathic Lower renal mass (in obese) causes: heroin use, HIV Focal and segmental sclerosis Hyalinosis Hypercellular mesangium Thick B.M.
Katholieke Universiteit Leuven: Research The heparan sulfate proteoglycans are missing from the glomerular wall in congenitallipoid nephrosis, and accumulate in excessive amounts in the amyloid http://www.kuleuven.ac.be/research/keydomains/medicine/diagnostic_agents1/med1_2
Extractions: Research topics Heparan sulfate proteoglycans are proteins that carry one or more complex carbohydrate chains of the heparan sulfate type. They are expressed at the cell surface and in the extracellular matrix in the immediate vicinity of the cells. The heparan sulfate chains bind and activate a specific group of extracellular matrix components, growth factors, enzymes and enzyme inhibitors, but also repel a variety of components. The heparan sulfate proteoglycans are involved in cell-cell and cell-matrix adhesion, modulate cellular responses to growth and differentiation factors, and are important determinants of the anticoagulant and filtrating properties of the vascular wall. The heparan sulfate proteoglycans are missing from the glomerular wall in congenital lipoid nephrosis, and accumulate in excessive amounts in the amyloid plaques of Alzheimer's disease and other neurodegenerative syndromes. A panel of monoclonal antibodies has been developed that traces three of the cell surface bound heparan sulfate proteoglycans (fibroglycan, glypican and syndecan) and the major heparan sulfate proteoglycan from basement membranes or pericellular matrices. In addition, monoclonal antibodies have been developed against epitopes in native heparan sulfate chains and against neo-epitopes produced by the enzyme heparitinase, allowing to trace and purify any heparan sulfate proteoglycan or heparitinase generated core protein preparation.
DAHAN K NIAUDET P. lipoid nephrosis in childhood. Rev. Prat., 53 (18), 20272032,2003 ; (Facteur d Impact 2001 X) (Services cités Néphrologie http://www.necker.fr/irnem/Unites 2003/03nephroped.htm
Extractions: Any Language English Afrikaans Arabic Bahasa Melayu Belarusian Bulgarian Catala Chinese Simplified Chinese Traditional Cymraeg Czech Dansk Deutsch Eesti Espanol Euskara Faroese Francais Frysk Galego Greek Hebrew Hrvatski Indonesia Islenska Italiano Japanese Korean Latvian Lietuviu Lingua Latina Magyar Netherlands Norsk Polska Portugues Romana Russian Shqip Slovensko Slovensky Srpski Suomi Svenska Thai Turkce Ukrainian Vietnamese Mode
Blackwell Synergy - Cookie Absent Clin Nephrol 47 289297, 1997 MEDLINE Abstract ISI Abstract. 15. Matsumoto KDecreased release of IL-10 by monocytes from patients with lipoid nephrosis. http://www.blackwell-synergy.com/links/doi/10.1111/j.1523-1755.2004.00392.x/enha
Extractions: Home An Error Occurred Setting Your User Cookie A cookie is a small amount of information that a web site copies onto your hard drive. Synergy uses cookies to improve performance by remembering that you are logged in when you go from page to page. If the cookie cannot be set correctly, then Synergy cannot determine whether you are logged in and a new session will be created for each page you visit. This slows the system down. Therefore, you must accept the Synergy cookie to use the system. What Gets Stored in a Cookie? Synergy only stores a session ID in the cookie, no other information is captured. In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a web site to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it. Please read our for more information about data collected on this site.
Blackwell Synergy - Cookie Absent 3, R ICH AR A hitherto undescribed vulnerability of the juxtamedullary glomeruliin lipoid nephrosis. Bull Johns Hopkins Hosp 100173 186, 1957. http://www.blackwell-synergy.com/links/doi/10.1046/j.1523-1755.1998.00845.x/enha
Extractions: Home An Error Occurred Setting Your User Cookie A cookie is a small amount of information that a web site copies onto your hard drive. Synergy uses cookies to improve performance by remembering that you are logged in when you go from page to page. If the cookie cannot be set correctly, then Synergy cannot determine whether you are logged in and a new session will be created for each page you visit. This slows the system down. Therefore, you must accept the Synergy cookie to use the system. What Gets Stored in a Cookie? Synergy only stores a session ID in the cookie, no other information is captured. In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a web site to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it. Please read our for more information about data collected on this site.
International Classification Of Diseases, Icd-9, Code 581.3 With lesion of minimal change glomerulonephritis. lipoid nephrosisMinimal change glomerular disease glomerulitis nephrotic syndrome http://www.centralx.com/diseases/icd511.htm
Extractions: Home Page References on the Intra-Arterial Administration of Agents Using ALZET Osmotic Pumps (IA-Q4-2003) 2ML1; 1 week; Controls received mp w/ vehicle; functionality of mp verified by residual volume; dose-response (p. 181, 183); cardiovascular; peptides. 2ML1; 24 hours; Cardiovascular; peptides; MCP-1 is monocyte chemoattractant protein 1. 2ML2; 3,7 days; Study proliferation of collateral arteries and capillaries. 2ML2; 18 days; Controls received mp w/ vehicle. 1007D; Controls received mp w/ vehicle; peptides. Yang HT, Yan Z, Abraham JA, Terjung RL. VEGF 2002; 14 days; Controls received mp w/ vehicle; cardiovascular; peptides; vehicle was PBS w/ 10% sodium citrate and 1.6% glycerol; sodium citrate used to prevent coagulation; glycerol used to enhance protein stability. 2002; 14 days; controls received mp w/ vehicle; dose response; peptides, cardiovascular; recomb. human FGF used; sodium citrate used to maintain catheter patency; glycerol used to stabilize protein. 2002; 2 weeks; controls received mp w/vehicle; functionality of mp verified by residual volume; peptides; human. recomb fibroblast growth factor used. 2ML4; 28 days; pump diagram (p. 888); 22 g intravenous catheter was inserted into tygon tubing; "implantable osmotic pumps offer an alternative simple delivery method, providing a constant release of soluble agents in a steady-state fashion." (p. 892); controls received mp w/vehicle; good methods (pp. 887-888); cardiovascular; peptides.
